Vertex Pharmaceuticals Inc / Ma
VRTXNasdaqCIK 875320HealthcareFiscal year ends Dec 31
Reports and events: 289 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-05-1808:56 ET | 8-K | 5.07 Shareholder vote results | 0000875320-23-000015 |
| 2023-05-0216:07 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000875320-23-000012 |
| 2023-05-0116:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-23-000010 |
| 2023-04-0616:34 ET | DEF 14A | Proxy statement | 0001308179-23-000591 |
| 2023-02-1016:12 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000875320-23-000007 |
| 2023-02-0716:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-23-000004 |
| 2022-10-2816:07 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000875320-22-000038 |
| 2022-10-2716:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-22-000036 |
| 2022-08-0516:06 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000875320-22-000030 |
| 2022-08-0416:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-22-000026 |
| 2022-07-1108:14 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000875320-22-000022 |
| 2022-07-0516:08 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation | 0000875320-22-000019 |
| 2022-05-2308:41 ET | 8-K | 8.01 Other events | 0000875320-22-000017 |
| 2022-05-1816:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-154021 |
| 2022-05-0616:03 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000875320-22-000014 |
| 2022-05-0516:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-22-000011 |
| 2022-04-0716:05 ET | DEF 14A | Proxy statementPeriod 2022-05-18 | 0001308179-22-000210 |
| 2022-02-0916:37 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000875320-22-000007 |
| 2022-01-2616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-22-000003 |
| 2021-11-0316:18 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000875320-21-000033 |
| 2021-11-0216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-21-000031 |
| 2021-07-3016:10 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0000875320-21-000027 |
| 2021-07-2916:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-21-000024 |
| 2021-06-2407:41 ET | 8-K | 8.01 Other events | 0000875320-21-000020 |
| 2021-05-1916:02 ET | 8-K | 5.07 Shareholder vote results | 0000875320-21-000018 |
| 2021-04-3016:19 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0000875320-21-000015 |
| 2021-04-2916:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-21-000012 |
| 2021-04-2008:03 ET | 8-K | 1.01 Entry into a material agreement | 0000875320-21-000009 |
| 2021-04-0816:03 ET | DEF 14A | Proxy statementPeriod 2021-05-19 | 0001308179-21-000196 |
| 2021-02-1116:03 ET | 10-K | Annual reportPeriod 2020-12-31 | 0000875320-21-000006 |
| 2021-02-0116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-21-000003 |
| 2020-11-2008:48 ET | 8-K | 8.01 Other events | 0000875320-20-000045 |
| 2020-10-3016:13 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0000875320-20-000043 |
| 2020-10-2916:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-20-000041 |
| 2020-09-2116:14 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0000875320-20-000037 |
| 2020-09-0316:12 ET | SC 13D | Ownership report, active investor | 0000875320-20-000034 |
| 2020-07-3116:18 ET | 10-Q | Quarterly reportPeriod 2020-06-30 | 0000875320-20-000030 |
| 2020-07-3018:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-20-000027 |
| 2020-06-0316:21 ET | 8-K | 5.07 Shareholder vote results | 0000875320-20-000023 |
| 2020-05-0120:37 ET | 10-Q | Quarterly reportPeriod 2020-03-31 | 0000875320-20-000019 |
| 2020-04-2920:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-20-000014 |
| 2020-04-2820:06 ET | DEF 14A | Proxy statementPeriod 2020-06-03 | 0001308179-20-000229 |
| 2020-04-0120:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000875320-20-000011 |
| 2020-02-1321:48 ET | 10-K | Annual reportPeriod 2019-12-31 | 0000875320-20-000007 |
| 2020-01-3021:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-20-000003 |
| 2019-10-3120:19 ET | 10-Q | Quarterly reportPeriod 2019-09-30 | 0000875320-19-000057 |
| 2019-10-3020:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-19-000053 |
| 2019-10-2411:23 ET | 8-K | 8.01 Other events | 0000875320-19-000050 |
| 2019-10-2120:02 ET | 8-K | 7.01 Regulation FD disclosure | 0000875320-19-000048 |
| 2019-09-1721:08 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 2.04 Item not in the standard list | 0000875320-19-000046 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 3, 2026, 18:50 ET. Listed shows no prices and gives no investment advice.